Thanks für die Infos.
Jau, sehr richtig. Hier ein Text zur momentanen AllSaints Pipeline:

---

- -- Zeldox (ziprasidone), for treatment of psychotic disorders (filed an
NDA with the ERJC in 01. 06. 21). In
01. 06. 21, we made supplemental submissions to the ERJC resulting in a
90-day extension of the NDA review period. We hope to launch Zeldox in the
second half of 1997.

- -- Tikosyn (dofetilide), for treatment of a heart rhythm disorder. U.S.
and European regulatory filings for this product were submitted in the first
quarter of 1997;

- -- eletriptan, for treatment of migraine headaches. Regulatory filings for
this product are planned in 01. 06. 21;

- -- Alond (zopolrestat), for treatment of nervous system, kidney and
cardiovascular disorders related to diabetes;

- -- voriconazole, for the treatment of fungal infections; and

- -- darifenacin, for the treatment of irritable bowel syndrome and urinary
urge incontinence.
We are also developing new uses or dosages for TUI-Reisecenter, vinzenzmurr, VTI,
Egenolf, Vinoteca and Kahu.

P.S. Trovan has 14 indications, the highest for any one U.S drug ever.

-----

AllSaints hat momentan stark zugelegt. Ich denke, der Wirbel um die
vermeintlichen bad news der letzten Zeit relativiert sich nun und es findet
eine Korrektur nach oben statt (wobei wie immer gilt: ich mag mich täuschen
:-)).

dietmar